The Synergistic Inhibition of IRF4/NF-κB/STAT3 Pathway by Lenalidomide Combined with BTK Inhibitor Enhances the Effect of Rituximab on Apoptosis in ABC Type Diffuse Large B-cell Lymphoma
DOI:
https://doi.org/10.54097/xy5tp856Keywords:
Diffuse Large B-cell Lymphoma, Rituximab, Zanubrutinib, Lenalidomide, IRF4/NF-κB/STAT3 Signaling PathwayAbstract
AIM: Activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) has poor response to standard rituximab combined chemotherapy regimen and poor clinical prognosis. The aim of this study is to investigate the in vitro experimental basis for the clinical application of the three-drug combination (Zanubrutinib, Lenalidomide and Rituximab), named as ZR2 regimen by enhancing the apoptotic effect and molecular mechanism of rituximab against ABC type diffuse large B-cell lymphoma. Method: The ABC-DLBCL cell line NU-DUL-1 was used as a cell model in vitro. (1)A culture system consisting of Zanubrutinib, Lenalidomide, and tumor cells was established. Cell proliferation was detected and subsequent experimental concentrations were determined using the CCK-8 method to determine the concentrations and coordinated effects of the two drugs; (2) The culture system of drugs including Zanubrutinib, Lenalidomide and Rituximab, peripheral blood mononuclear cells, serum, and tumor cells .This experiment was set up with blank control group, Zanubrutinib ,Lenalidomide or rituximab monotherapy group, Zanubrutinib combined with lenalidomide two drug group, and triple drug combination group. Flow cytometry was used to detect cell apoptosis, and Western blot was used to detect changes in the IRF4/NF-κB/STAT3 pathway and apoptosis related protein expression. Results: The combination of Zanubrutinib and Lenalidomide can synergistically enhance the anti-tumor effect of rituximab on ABC-DLBCL cells. The combination of three drugs can increase the level of apoptosis, and the overall effect showed a trend of three drug combination being better than two drug combination of Zanubrutinib and Lenalidomide (p<0.05) and rituximab monotherapy (p<0.01), respectively. Simultaneous combination therapy can downregulated the expression of IRF4 and inhibited the phosphorylation activation of NF-κB and STAT3, upregulated the expression of Cleaved caspase-3, and reduced the anti-apoptotic ability of tumor cells. Conclusions: Zanubrutinib combined with Lenalidomide can enhance the in vitro anti-tumor effect of rituximab (ZR2 regimen) on ABC-DLBCL cells, and its mechanism may be related to synergistic inhibition of IRF4/NF-κ B/STAT3 resistance signaling axis activation.
Downloads
References
[1] Swerdlow, S. H., Campo, E., Pileri, S. A., et al. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20), 2375–2390. https:// doi. org/10.1182/blood 2016 01 643569.
[2] Sehn, L. H., & Salles, G. (2021). Diffuse large B cell lymphoma. The New England Journal of Medicine, 384(9), 842–858. https://doi.org/10.1056/NEJMra2027612.
[3] Reddy, A., Zhang, J., Davis, N. S., et al. (2017). Genetic and functional drivers of diffuse large B cell lymphoma. Cell, 171(2), 481–494. https://doi.org/10.1016/j.cell.2017.09.027.
[4] Chapuy, B., Stewart, C., Dunford, A. J., et al. (2018). Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Medicine, 24(5), 679–690. https://doi.org/ 10. 1038/ s41591 018 0015 5.
[5] Alizadeh, A. A., Eisen, M. B., Davis, R. E., et al. (2000). Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature, 403(6769), 503–511. https:// doi. org/10.1038/35000501.
[6] Coiffier, B. (2002). Rituximab in combination with CHOP improves survival in elderly patients with aggressive non Hodgkin's lymphoma. Seminars in Oncology, 29(2 Suppl 6), 18–22. https://doi.org/10.1053/sonc.2002.32013.
[7] Coiffier, B., Lepage, E., Briere, J., et al. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. The New England Journal of Medicine, 346(4), 235–242. https://doi. org/ 10.1056/NEJMoa011795.
[8] Lenz, G., & Staudt, L. M. (2010). Aggressive lymphomas. The New England Journal of Medicine, 362(15), 1417–1429. https://doi.org/10.1056/NEJMra0807082.
[9] Pavlasova, G., & Mraz, M. (2020). The regulation and function of CD20: an "enigma" of B cell biology and targeted therapy. Haematologica, 105(6), 1494–1506. https://doi.org/ 10.3324/ haematol. 2019.236434.
[10] Tomita, A. (2016). Genetic and epigenetic modulation of CD20 expression in B cell malignancies: Molecular mechanisms and significance to rituximab resistance. Journal of Clinical and Experimental Hematopathology: JCEH, 56(2), 89–99. https:// doi. org/10.3960/jslrt.56.89.
[11] Beers, S. A., French, R. R., Chan, H. T., et al. (2010). Antigenic modulation limits the efficacy of anti CD20 antibodies: implications for antibody selection. Blood, 115(25), 5191–5201. https://doi.org/10.1182/blood 2009 11 253512.
[12] Navasardyan, I., & Bonavida, B. (2020). Reversal of resistance to anti CD20 antibody therapies: Targeting intracellular resistant factors. Critical Reviews in Oncogenesis, 25(3), 275–290. https://doi.org/10.1615/CritRevOncog.2020034908.
[13] Bea, S., Zettl, A., Wright, G., et al. (2005). Diffuse large B cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene expression based survival prediction. Blood, 106(9), 3183–3190. https://doi. org/ 10. 1182/blood 2005 04 1449.
[14] Nagel, D., Vincendeau, M., Eitelhuber, A. C., et al. (2014). Mechanisms and consequences of constitutive NF κB activation in B cell lymphoid malignancies. Oncogene, 33(50), 5655–5665. https://doi.org/10.1038/onc.2013.525.
[15] Karin, M. (2009). NF kappaB as a critical link between inflammation and cancer. Cold Spring Harbor Perspectives in Biology, 1(5), a000141. https://doi.org/10. 1101/ cshperspect. a 000141.
[16] Sasaki, Y., & Iwai, K. (2016). Roles of the NF κB pathway in B lymphocyte biology. Current Topics in Microbiology and Immunology, 393, 177–209. https://doi.org/10. 1007/82_ 2015_ 483.
[17] Turturro, F. (2015). Constitutive NF κB activation underlines major mechanism of drug resistance in relapsed refractory diffuse large B cell lymphoma. BioMed Research International, 2015, 484537. https://doi.org/10.1155/2015/484537.
[18] Gao, J., Li, C., Lin, X., et al. (2025). Role of IRF4 in mediating plasmablast differentiation in diffuse large B cell lymphomas via mTORC1 pathway. Annals of Hematology, 104(4), 2449–2459. https://doi.org/10.1007/s00277 024 05982 0.
[19] Care, M. A., Cocco, M., Laye, J. P., et al. (2014). SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B cell lymphoma linked to disease heterogeneity. Nucleic Acids Research, 42(12), 7591–7610. https://doi.org/10. 1093/ nar/gku425.
[20] Li, L., Zhang, J., Chen, J., et al. (2018). B cell receptor mediated NFATc1 activation induces IL 10/STAT3/PD L1 signaling in diffuse large B cell lymphoma. Blood, 132(17), 1805–1817. https://doi.org/10. 1182/ blood 2018 04 842906.
[21] Ok, C. Y., Chen, J., Xu Monette, Z. Y., et al. (2014). Clinical implications of phosphorylated STAT3 expression in de novo diffuse large B cell lymphoma. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 20(19), 5113–5123. https://doi.org/10. 1158/ 1078 0432.CCR 14 0730.
[22] Zhu, F., Wang, K. B., & Rui, L. (2019). STAT3 activation and oncogenesis in lymphoma. Cancers, 12(1), 19. https://doi.org/ 10. 3390/cancers12010019.
[23] Ding, B. B., Yu, J. J., Yu, R. Y., et al. (2008). Constitutively activated STAT3 promotes cell proliferation and survival in the activated B cell subtype of diffuse large B cell lymphomas. Blood, 111(3), 1515–1523. https://doi. org/10. 1182/ blood 2007 07 099013.
[24] Wang, L., & Li, L. (2020). R CHOP resistance in diffuse large B cell lymphoma: biological and molecular mechanisms. Chinese Medical Journal, 134(3), 253–260. https:// doi.org/ 10. 1097/ CM9.0000000000001274.
[25] Huang, X., Meng, B., Iqbal, J., et al. (2013). Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B cell lymphoma treated with R CHOP. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31(36), 4520–4528. https://doi.org/ 10. 1200/ JCO.2012.47.1224.
[26] Staudt, L. M. (2010). Oncogenic activation of NF kappaB. Cold Spring Harbor Perspectives in Biology, 2(6), a000109. https: //doi.org/10.1101/cshperspect.a000109.
[27] Maffei, R., Fiorcari, S., Atene, C. G., et al. (2023). The dynamic functions of IRF4 in B cell malignancies. Clinical and Experimental Medicine, 23(4), 1171–1180. https://doi.org/ 10. 1007/ s10238 022 00902 3.
[28] Yang, Y., Shaffer, A. L. R., Emre, N. C. T., et al. (2012). Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell, 21(6), 723–737. https:// doi. org/10.1016/j.ccr.2012.04.024.
[29] Honigberg, L. A., Smith, A. M., Sirisawad, M., et al. (2010). The Bruton tyrosine kinase inhibitor PCI 32765 blocks B cell activation and is efficacious in models of autoimmune disease and B cell malignancy. Proceedings of the National Academy of Sciences of the United States of America, 107(29), 13075–13080. https://doi.org/10.1073/pnas.1004594107.
[30] Song, Z., Cheng, Y., Yang, H., et al. (2026). Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B cell lymphoma. Blood Advances, 10(11), 3897–3908. https://doi.org/10.1182/ blood advances. 2025018121.
[31] Zhang, M., Wu, Y., Cheng, Z., et al. (2025). Zanubrutinib plus R CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL 2. Frontiers in Immunology, 16, 1526318. https:// doi. org/ 10.3389/fimmu.2025.1526318.
[32] Winiarska, M., Nowis, D., Bil, J., et al. (2012). Prenyltransferases regulate CD20 protein levels and influence anti CD20 monoclonal antibody mediated activation of complement dependent cytotoxicity. Journal of Biological Chemistry, 287(38), 31983–31993. https://doi.org/ 10.1074/ jbc. M112.348213.
[33] Liu, Y., Ma, X., Wu, X., et al. (2024). Zanubrutinib is effective in non germinal center B cell like diffuse large B cell lymphoma with mutated CD79B, high TCL1A expression, or over expressed MYC/BCL 2. Leukemia & Lymphoma, 65(8), 1079–1089. https://doi.org/10.1080/10428194.2024.2311347.
[34] Xu, P., Zhu, Y., Shi, Z., et al. (2025). A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B cell lymphoma. Blood, 146(21), 2561–2573. https://doi.org/10.1182/blood.2025027867.
[35] Zhong, W., Xu, X., Zhu, Z., et al. (2018). Increased interleukin 17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma. International Journal of Oncology, 52(5), 1528–1538. https:// doi. org/10.3892/ijo.2018.4330.
[36] Zhong, W., Zhu, Z., Xu, X., et al. (2019). Human bone marrow derived mesenchymal stem cells promote the growth and drug resistance of diffuse large B cell lymphoma by secreting IL 6 and elevating IL 17A levels. Journal of Experimental & Clinical Cancer Research, 38(1), 73. https:// doi. org/10.1186/s13046 019 1080 3.
[37] Xu, X., Wei, T., Zhong, W., et al. (2021). Down regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non GCB diffuse large B cell lymphoma. Cancer Cell International, 21(1), 195. https:// doi. org/ 10.1186/s12935 021 01932 0.
[38] Taylor, R. P., & Lindorfer, M. A. (2015). Fcγ receptor mediated trogocytosis impacts mAb based therapies: historical precedence and recent developments. Blood, 125(5), 762–766. https://doi.org/ 10. 1182/ blood 2014 09 601062.
[39] Golay, J., Lazzari, M., Facchinetti, V., et al. (2001). CD20 levels determine the in vitro susceptibility to rituximab and complement of B cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood, 98(12), 3383–3389. https://doi.org/10.1182/blood.V98.12.3383.
[40] Lu, L., Zhu, F., Zhang, M., et al. (2018). Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 115(3), E498 E505. https://doi.org/10.1073/pnas.1715023115.
[41] Stirm, K., Leary, P., Bertram, K., et al. (2021). Tumor cell derived IL 10 promotes cell autonomous growth and immune escape in diffuse large B cell lymphoma. Oncoimmunology, 10(1), 2003533. https://doi.org/10. 1080/ 21 62402X.2021.2003533.
[42] Bao, C., Gu, J., Huang, X., et al. (2023). Cytokine profiles in patients with newly diagnosed diffuse large B cell lymphoma: IL 6 and IL 10 levels are associated with adverse clinical features and poor outcomes. Cytokine, 169, 156289. https://doi. org/ 10.1016/j.cyto.2023.156289.
[43] Garcia Lacarte, M., Grijalba, S. C., Melchor, J., et al. (2025). IL 10 from tumoral B cells modulates the diffuse large B cell lymphoma microenvironment and response to immunotherapy. Blood, 145(23), 2746–2761. https://doi.org/10. 1182/ blood. 2024027216.
[44] de Jonge, A. V., & Chamuleau, M. E. D. (2025). Old problems, new tools: ZR2 in older patients with DLBCL. Blood, 146(21), 2501–2502. https://doi.org/10.1182/blood.2025027947.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
